The Evolution Capital report is not independent — it is a paid promotion, as clearly disclosed in the disclaimer.
The CEO appears heavily incentivised to drive up the share price. Personally, I’d prefer to see more focus on building the business through commercial deals and partnerships. If the technology is truly revolutionary, as claimed, it shouldn’t be difficult to start converting hospital trials into paying customers , especially if the company genuinely has a durable moat and an active miscellaneous code for reimbursements as claimed.
Spending shareholder funds on roadshows and promotional reports that add no clear operational value to the business is concerning. The priority should be on execution, not optics.
(20min delay)